Allergan, Inc. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 128

Allergan, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Allergan, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Allergan, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Allergan, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Allergan, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Allergan, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Allergan, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Allergan, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Allergan, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Allergan, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Allergan, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Allergan, Inc. Snapshot
Allergan, Inc. Overview
Key Information
Key Facts
Allergan, Inc. – Research and Development Overview
Key Therapeutic Areas
Allergan, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Allergan, Inc. – Pipeline Products Glance
Allergan, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Allergan, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Allergan, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Allergan, Inc. – Drug Profiles
ZYMAR X
Product Description
Mechanism of Action
R&D Progress
Bimatoprost + Brimonidine Tartrate + Timolol maleate
Product Description
Mechanism of Action
R&D Progress
Botox
Product Description
Mechanism of Action
R&D Progress
Botulinum Toxin Type A
Product Description
Mechanism of Action
R&D Progress
Ozurdex
Product Description
Mechanism of Action
R&D Progress
SER120
Product Description
Mechanism of Action
R&D Progress
AGN 203818
Product Description
Mechanism of Action
R&D Progress
AGN-210669
Product Description
Mechanism of Action
R&D Progress
AGN-210961
Product Description
Mechanism of Action
R&D Progress
AGN-210961 + Lumigan
Product Description
Mechanism of Action
R&D Progress
AGN-214868
Product Description
Mechanism of Action
R&D Progress
AGN208397
Product Description
Mechanism of Action
R&D Progress
Botox
Product Description
Mechanism of Action
R&D Progress
Brimonidine — DDS
Product Description
Mechanism of Action
R&D Progress
IOP Lowering (EP Agonist)
Product Description
Mechanism of Action
R&D Progress
IOP Lowering (Sustained Release)
Product Description
Mechanism of Action
R&D Progress
RESTASIS X
Product Description
Mechanism of Action
R&D Progress
AGN-207281
Product Description
Mechanism of Action
R&D Progress
Botox
Product Description
Mechanism of Action
R&D Progress
Sanctura XR + Glucophage
Product Description
Mechanism of Action
R&D Progress
TKI
Product Description
Mechanism of Action
R&D Progress
Allergan, Inc. – Pipeline Analysis
Allergan, Inc. – Pipeline Products by Therapeutic Class
Allergan, Inc. Pipeline Products By Target
Allergan, Inc. – Pipeline Products by Route of Administration
Allergan, Inc. – Pipeline Products by Molecule Type
Allergan, Inc. – Recent Pipeline Updates
Allergan, Inc. - Dormant Projects
Allergan, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AGN-201781
Memantine
Sirna-027
Allergan, Inc. – Company Statement
Allergan, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Allergan, Inc. - Key Manufacturing Facilities
Recent Developments
Oct 15, 2010: Allergan Receives FDA Approval For BOTOX For Treatment Of Chronic Migraine
Sep 24, 2010: Allergan Receives FDA Approval For OZURDEX As Treatment For Non-Infectious Uveitis
Sep 24, 2010: Allergan Receives FDA Approval For OZURDEX As Treatment For Non-Infectious Uveitis
Aug 31, 2010: Allergan Receives FDA Approval For LUMIGAN 0.01% For Reduction Of Elevated Intraocular Pressure In Glaucoma Patients
Aug 31, 2010: Allergan Receives FDA Approval For LUMIGAN 0.01% For Reduction Of Elevated Intraocular Pressure In Glaucoma Patients
Aug 31, 2010: Allergan Receives FDA Approval For LUMIGAN 0.01% For Reduction Of Elevated Intraocular Pressure In Glaucoma Patients
Jul 28, 2010: Allergan Receives EMA Marketing Authorization For OZURDEX For Retinal Disease
Jul 09, 2010: Allergan's BOTOX Receives Authorization In UK For Treatment Of Chronic Migraine
May 21, 2010: Allergan expected to launch Ozurdex in Europe in Q3
May 21, 2010: Allergan expected to launch Ozurdex in Europe in Q3
Financial Deals Landscape
Allergan, Inc., Deals Volume Summary, 2004 to YTD 2010
Allergan, Inc., Deals Summary By Region, 2004 to YTD 2010
Allergan, Inc., Deals Summary, 2004 to YTD 2010
Allergan, Inc. Detailed Deal Summary
Asset Purchase
Maguire Properties sells an office property to Allergan
Acquisition
Allergan Acquires Esprit Pharma
Allergan Acquires EndoArt
Allergan Acquires Groupe Corneal Laboratoires
Allergan Acquires Inamed
Venture Financing
BAROnova Secures $7.5 million In Series B Financing
Debt Offering
Allergan Completes Private Placement Of $750 Million
Allergan Completes Private Placement Of $800 Million
Quintiles Enters Into Co-Promotion Agreement With Allergan
Pieris Enters Into Co-Development Agreement With Allergan
Allergan Forms Joint Venture With Samil Pharmaceutical
ACADIA Pharmaceuticals Expands Co-Development Agreement With Allergan
ExonHit Therapeutics Amends Co-Development Agreement With Allergan
Allergan Enters Into Co-Development Agreement With Polyphor
Allergan Enters Into Co-Development Agreement With Spectrum Pharmaceuticals
ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan
Allergan Enters Into Strategic Collaboration With Clinique Laboratories
Stiefel Laboratories Enters Into Co-Development Agreement With Allergan
ExonHit Therapeutics Expands Co-Development Agreement With Allergan
ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan
Sirna Therapeutics Enters Into Co-Development Agreement With Allergan
Valeant Pharmaceuticals Enters Into Co-Marketing Agreement With Allergan
PediaMed Enters Into Co-Promotion Agreement With Allergan
Pediamed Enters Into Co-Promotion Agreement With Allergan
Lupin Pharmaceuticals Enters Into Co-Promotion Agreement With Allergan
Laboratoires Pierre Fabre Enters Into Agreement With Allergan
Allergan Terminates Co-Development Agreement With Peplin
Licensing Agreements
BTG Enters Into Licensing Agreement With Allergan
Pieris Enters Into Licensing Agreement With Allergan
Asterand Enters Into Licensing Agreement With Allergan
Indevus And Rottapharm Enters Into Licensing Agreement With Allergan
Syntaxin Enters Into Research And Licensing Agreement With Allergan
Allergan Enters Into An Agreement With GlaxoSmithKline
Pharmacopeia Enters Into Licensing Agreement With Allergan
Allergan Enters Into Licensing Agreement With Sanwa Kagaku Kenkyusho
Allergan Amends Licensing Agreement With Genzyme
Allergan Enters Into Licensing Agreement With Kyorin Pharmaceutical
Allergan Enters Into Licensing Agreement With Senju Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• Aerospace and Defence Industry - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Electronic Warfare Systems - Global Strategic Business Report